# Wolverine (BPC-157 + TB-500): Research Overview — Peptide Emporium > A plain-English research summary of the Wolverine peptide blend — BPC-157 paired with TB-500. Covers the two-mechanism rationale, what the published evidence actually says, and the key cautions. Citations throughout. BPC-157 for angiogenesis, TB-500 for cell migration — two separately characterized mechanisms paired in one blend. The synergy claim is a reasonable theory. No combination study exists. ## The short version The Wolverine blend is a research-community pairing of two peptides: [BPC-157](/bpc-157) and [TB-500](/tb-500). It is not a single chemical compound but a co-formulated combination sold by research suppliers, sometimes in a single vial. The rationale is that the two peptides work through *different, non-overlapping* repair mechanisms — BPC-157 encourages new blood vessels to grow into damaged tissue via the VEGFR2 pathway [4], while TB-500 (via its parent protein thymosin beta-4) regulates the actin skeleton that cells use to crawl toward a wound [10]. Here is the honest framing: no peer-reviewed study has tested BPC-157 and TB-500 together in a controlled experiment. Every claim about the blend's effect in humans is extrapolated from each peptide's independent, overwhelmingly preclinical record. Both components are WADA-prohibited, neither is an approved drug, and no human dose is listed on this page. ## What it is Wolverine is not a single molecule. It is a co-formulation of two distinct synthetic peptides: 1. **BPC-157** — a fifteen-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; ~1419.5 Da) derived from a protein in human gastric juice. 2. **TB-500** — a synthetic N-acetylated heptapeptide (Ac-LKKTETQ; ~889.0 Da) corresponding to the actin-binding region (residues 17-23) of thymosin beta-4. The blend has no single CAS number or molecular weight. Research suppliers commonly offer it as a single reconstituted vial. The two peptides are co-dissolved, not chemically bonded, and their individual pharmacokinetics differ: BPC-157 has an elimination half-life under 30 minutes [3], while TB-500 and its parent protein behave differently — a pharmacokinetic mismatch that makes "simultaneous effect" claims complicated. ## How it is supposed to work The Wolverine rationale is a two-pathway story. BPC-157 is described as the *angiogenic* half: in animal and cell models it upregulates the VEGFR2 vessel-growth receptor and activates the downstream VEGFR2-Akt-eNOS pathway, encouraging blood-vessel formation and restoring circulation to ischemic tissue [4]. TB-500 (with the important caveat that evidence comes mostly from full-length thymosin beta-4, not the fragment) is described as the *cell-migration* half: it sequesters monomeric actin 1:1 via the LKKTETQ motif, regulating the cytoskeletal dynamics that drive cells toward a wound, reduce scarring, and recruit progenitors [10]. The blend's marketing positions these as complementary arms of the same cascade — grow a blood supply in, then fill in the wound. The theory is internally consistent. The problem is that it is purely theoretical for the combination: no controlled head-to-head or co-administration study exists that would define a synergistic dose, ratio, or endpoint for the two given together. ## What the research shows *The state of the blend evidence.* A 2025 systematic review of BPC-157 in orthopaedic sports medicine covered 36 studies (35 preclinical, only one human — a 12-patient retrospective intra-articular knee-pain report). It found no clinical safety data and reached a level IV-V (lowest-tier) evidence conclusion for BPC-157 alone; it makes no mention of TB-500 or any combination [23]. That is the clearest published statement that the Wolverine combination has no controlled clinical evidence. *BPC-157 component.* A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, rigorous large-scale trials are lacking, and the peptide should be treated as investigational [2]. The 2017 VEGFR2 mechanistic study establishes the angiogenic mechanism for BPC-157's component contribution [4]. *TB-500 component.* A 2026 Sports Medicine review of unapproved peptides for musculoskeletal injury — listing both BPC-157 and TB-500/thymosin beta-4 — concludes that animal-model promise has not been matched by rigorous human safety data, and that these compounds operate largely outside regulatory oversight [8]. The thymosin beta-4 mechanism review consolidates the actin-migration rationale for TB-500's component contribution [10]. ## Reported effects, cautions & safety The blend inherits and compounds the cautions of both components: - *No combination study.* No peer-reviewed study has tested BPC-157 and TB-500 together. "Synergy" is mechanistic extrapolation, not direct evidence [23][2]. - *TB-500 identity caveat.* The "TB-500" fragment sold in the blend is Ac-LKKTETQ (~889 Da), but most efficacy data come from full-length thymosin beta-4 (~4,963 Da). The blend inherits this gap [8]. - *Both components are overwhelmingly preclinical.* BPC-157 has three small human pilots [2]; the TB-500 fragment has zero completed controlled human trials [8]. - *Tumor angiogenesis signal.* Both BPC-157 (via VEGFR2) and thymosin beta-4 are pro-angiogenic. Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis; the same pro-repair properties could theoretically support tumor growth [10]. - *Both components are WADA-prohibited.* Using either or both in an athletic context implicates anti-doping rules [8]. - *Unregulated supply.* Product identity, purity and the actual ratio of BPC-157 to TB-500 in any given vial are unverified outside formal studies. The KLOW blend on this site adds [GHK-Cu](/ghk-cu) and [KPV](/kpv) to this pairing. Community members report both benefits and adverse effects for KLOW — those are described on the [KLOW page](/klow). ## Where it fits in recovery research Wolverine sits at the intersection of the two most-studied repair peptides on this site. It is the blend that put BPC-157 and TB-500 together in the research-use community, and it is the conceptual core of the larger [KLOW](/klow) blend. Its two-mechanism rationale is coherent and the individual components have real preclinical depth — the honest caveat is that the combination itself has never been tested. That gap is not unusual in peptide research, but it is worth holding clearly. See the [compare page](/compare) to see how all six line up. ![Wolverine blend two-peptide repair signaling illustration in cold petrol tones](/images/wolverine.webp) --- A plain-English reading guide to the peer-reviewed recovery-peptide literature — research summaries only, never clinical advice and never a product for sale.